CY1118215T1 - Αντι-νεοπλασματικη ανοσοθεραπεια - Google Patents

Αντι-νεοπλασματικη ανοσοθεραπεια

Info

Publication number
CY1118215T1
CY1118215T1 CY20161101144T CY161101144T CY1118215T1 CY 1118215 T1 CY1118215 T1 CY 1118215T1 CY 20161101144 T CY20161101144 T CY 20161101144T CY 161101144 T CY161101144 T CY 161101144T CY 1118215 T1 CY1118215 T1 CY 1118215T1
Authority
CY
Cyprus
Prior art keywords
immunotherapy
neoplastic
treatment
patients
cancer
Prior art date
Application number
CY20161101144T
Other languages
English (en)
Inventor
Gilberto Filaci
Original Assignee
Mediolanum Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici S.P.A. filed Critical Mediolanum Farmaceutici S.P.A.
Publication of CY1118215T1 publication Critical patent/CY1118215T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρησιμοποίηση παραγόμενων από τελομεράση πεπτιδίων για τη θεραπευτική αγωγή οποιωνδήποτε καρκινοπαθών, ιδιαίτερα για τη θεραπευτική αγωγή ασθενών με καρκίνο του νεφρού ή του προστάτη.
CY20161101144T 2008-06-16 2016-11-09 Αντι-νεοπλασματικη ανοσοθεραπεια CY1118215T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16
PCT/EP2009/004337 WO2010003520A2 (en) 2008-06-16 2009-06-16 Anti-tumor immunotherapy

Publications (1)

Publication Number Publication Date
CY1118215T1 true CY1118215T1 (el) 2017-06-28

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101144T CY1118215T1 (el) 2008-06-16 2016-11-09 Αντι-νεοπλασματικη ανοσοθεραπεια

Country Status (14)

Country Link
US (1) US8828403B2 (el)
EP (1) EP2310044B1 (el)
JP (1) JP5787752B2 (el)
CA (1) CA2727388C (el)
CY (1) CY1118215T1 (el)
DK (1) DK2310044T3 (el)
ES (1) ES2602453T3 (el)
HR (1) HRP20161434T1 (el)
HU (1) HUE030984T2 (el)
LT (1) LT2310044T (el)
PL (1) PL2310044T3 (el)
PT (1) PT2310044T (el)
SI (1) SI2310044T1 (el)
WO (1) WO2010003520A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383894A (zh) * 2010-02-16 2018-08-10 阿尔特公司 多肽及其应用
KR20210025132A (ko) * 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US9730984B2 (en) 2012-05-11 2017-08-15 Gemvax & Kael Co., Ltd. Composition for preventing or treating rheumatoid arthritis
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI678374B (zh) * 2012-09-19 2019-12-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
CN110028554B (zh) * 2012-09-19 2023-04-07 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
ES2716870T3 (es) * 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN104508485B (zh) 2013-06-07 2017-01-18 杰姆维克斯&凯尔有限公司 在癌症免疫疗法中有用的生物标记
KR20160039152A (ko) * 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
RU2661596C2 (ru) 2013-10-23 2018-07-17 Джемвакс Энд Каэл Ко., Лтд. Композиция для лечения и профилактики доброкачественной гиперплазии простаты
WO2015072750A1 (ko) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
ES2818921T3 (es) 2013-11-22 2021-04-14 Gemvax & Kael Co Ltd Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo
KR102314231B1 (ko) * 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20230028596A (ko) 2016-04-07 2023-02-28 김상재 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
HRP20161434T1 (hr) 2017-02-24
JP2011524390A (ja) 2011-09-01
WO2010003520A3 (en) 2010-07-15
PL2310044T3 (pl) 2017-04-28
SI2310044T1 (sl) 2017-03-31
CA2727388A1 (en) 2010-01-14
ES2602453T3 (es) 2017-02-21
EP2310044B1 (en) 2016-08-24
WO2010003520A2 (en) 2010-01-14
JP5787752B2 (ja) 2015-09-30
PT2310044T (pt) 2016-11-18
EP2310044A2 (en) 2011-04-20
DK2310044T3 (en) 2016-12-12
CA2727388C (en) 2017-08-29
LT2310044T (lt) 2016-12-27
HUE030984T2 (en) 2017-06-28
US20110135692A1 (en) 2011-06-09
US8828403B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
CY1118215T1 (el) Αντι-νεοπλασματικη ανοσοθεραπεια
CY1120560T1 (el) Βελτιστοποιημενο συστημα παραδοσης in vivo me ενδοσωματολυτικους παραγοντες για συζευγματα νουκλεϊνικου οξεος
CY1124469T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
EA201171367A1 (ru) Винилиндазолильные соединения
CY1119567T1 (el) Θεραπευτικα πεπτιδια
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
EA201400178A1 (ru) Лечение рака молочной железы
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
CY1116289T1 (el) Θεραπευτικη αγωγη καρκινου του προστατη σε μεταστατικο σταδιο με δεγαρελιξη
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201391208A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201490944A1 (ru) Двойной ингибитор met и vegf для лечения рака
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
BR112013024211A2 (pt) tratamento de tumores sólidos
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY34582A (es) Anticuerpos anti-cxcr3
EA201591024A1 (ru) Димерные соединения